Recently, we have demonstrated that serum-derived IgG fractions from patients with scleroderma-associated renal crisis stimulate interleukin-6 (IL-6) production by targeting the protease-activated receptor 1 (PAR1) on ECs (23). This evidence concerns the gene IL6 and scleroderma.